<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801176</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A01188-33</org_study_id>
    <secondary_id>2011/1774</secondary_id>
    <nct_id>NCT01801176</nct_id>
  </id_info>
  <brief_title>Peripheral Primitive Fibromatosis</brief_title>
  <acronym>WS-RT Fibro</acronym>
  <official_title>Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's a monitoring study. The aim is to assess the progression free survival up to 3 years.
      Patients are not treated until progression. Search for scalability predictive factors and
      registration of treatments if progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional result</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed  with criteria for Adverse Effects-V4 scale once per year during the consultation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Primitive Fibromatosis</condition>
  <arm_group>
    <arm_group_label>Initial monitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months</description>
    <arm_group_label>Initial monitoring group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peripheral primitive fibromatosis

          -  Adults patients

          -  Peripheral primitive fibromatosis proved by biopsy

          -  Peripheral primitive fibromatosis R2 resected for which monitoring is decided

          -  MRI realized before inclusion

          -  Patient information and informed consent signed

        Exclusion Criteria:

          -  Local recur

          -  Head and neck topography

          -  Primitive fibromatosis R0 or R1 resected

          -  Specific medical treatment of fibromatosis

          -  Patient already included in an other clinical trial with an experimental molecule

          -  Persons deprived of liberty

          -  Impossibility to submit to the trial's medical follow-up for psychological,
             geographical or socials reasons

          -  Previous history of cancer

          -  Counter indication to the realization of an MRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie BONVALOT, MD</last_name>
      <phone>0142114383</phone>
      <phone_ext>+33</phone_ext>
      <email>bonvalot@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thibaud MOTREFF</last_name>
      <phone>0142116643</phone>
      <phone_ext>+33</phone_ext>
      <email>thibaud.motreff@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvie BONVALOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 27, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proved by biopsy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
